Global Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Report and Forecast 2024-2032

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Size

The chronic inflammatory demyelinating polyneuropathy therapeutics market is expected to grow at a CAGR of 6.60% during the forecast period of 2024-2032, driven by the rising introduction of new therapeutic options and increased R&D activities focused on managing the disorder across the 8 major markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Outlook

• One of the major market trends is the increased use of immunoglobulin therapy as an effective maintenance treatment in adults with CIDP.

• The market growth is influenced by the growing aging population, rising healthcare expenditure, and advancements in diagnostic technologies.

• Corticosteroids such as prednisone and prednisolone cover a significant market share in the drug type segment as they are relatively cheap as compared to their counterparts and offer long-term remission.

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Overview

Chronic inflammatory demyelinating polyneuropathy (CIDP) is defined as an auto-immune disorder in which the immune system attacks the myelin, which protects the body’s nerves. The common treatments for this neurological disorder include corticosteroids, plasma exchange, intravenous immunoglobulins, and chronic immunosuppressive agents. These therapeutics are either taken alone or in combination with two or more drugs.

The increase in healthcare spending by the government of emerging economies to improve neurological care is likely to augment the demand for chronic inflammatory demyelinating polyneuropathy therapeutics market. Moreover, the market is anticipated to be aided by the growing FDA approvals of immunoglobulin CDIP therapeutics which is propelling the production of CDIP drugs. Strategic collaborations between pharmaceutical laboratories aimed towards providing high-quality CDIP therapeutics are projected to provide impetus to the growth of the market in the coming years.

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Growth Drivers

Increasing Prevalence of Rising Chronic Inflammatory Demyelinating Polyneuropathy to Affect the Market Landscape Significantly
 
Recent data suggests that the prevalence of chronic inflammatory demyelinating polyneuropathy ranges from 0.7 to 10.3 cases per 100,000 individuals. In the United States, it is estimated that 5 to 7 people per 100,000 are suffering from this rare neuromuscular disorder. The acquired autoimmune disease tends to predominate in males, with a sex rate ratio reported to range from 1.5 to 4.  The increasing prevalence of this neurological disorder is driving the demand for CIDP therapeutics. In addition, the incidence is known to increase with advancing age. Thus, the market is being positively navigated by the rise in the geriatric population and sedentary lifestyles led by working-class adults.

Growth in Approval of Novel Therapeutics to Meet Rising Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Demand

In January 2024,  the US Food and Drug Administration (FDA) approved Takeda Pharmaceuticals’s HyQvia for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP). Indicated as a maintenance therapy for adults with CIDP, HyQvia is the only FDA-cleared combination of immunoglobulin (IG) and hyaluronidase. The approval was based on the positive results demonstrated in the late-stage ADVANCE-CIDP 1 study. This IG therapy is administered as a subcutaneous infusion and can also be self-administered after appropriate training. The surge in approval of such personalized maintenance treatment alternatives for CIDP is likely to drive the market growth in the forecast period.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Trends

The market is witnessing several trends and developments to improve the current global scenario. Some of the notable trends are as follows:

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Segmentation

Market Breakup by Drug Type

• Corticosteroids

• ntravenous Immunoglobulin Therapy (IVIG)

• Plasmapheresis (Plasma Exchange)

• Immunotherapy

• Stem Cell Transplant

• Others

Market Breakup by Route of Administration

• Oral

• Injectable

• Others

Market Breakup by Gender

• Male

• Female

Market Breakup by End User

• Hospitals

• Specialty Clinics

• Home Healthcare

• Others

Market Breakup by Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Market Breakup by Region

• United States

• EU-4 and the United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • United Kingdom

• Japan

• India

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Share

Market Segmentation Based on Drug Type is Anticipated to Witness Substantial Growth

The market segmentation by drug type includes corticosteroids, intravenous immunoglobulin therapy (IVIG), plasmapheresis (plasma exchange), immunotherapy, and stem cell transplant, among others. Corticosteroids reduce inflammation and hamper the efficiency of the immune system and are known to improve the health of around 60% of patients. Hence, this drug type is witnessing a significant demand in the healthcare industry. In addition to this, these drugs are easy to administer, relatively cheap as compared to their counterparts, and offer long-term remission in chronic inflammatory demyelinating polyneuropathy. Consequently, this drug type is poised to augment the chronic inflammatory demyelinating polyneuropathy therapeutics market demand.

In addition, the response rate of corticosteroids is high, which is anticipated to be a major driving factor of the segment in the forecast period. In the coming years, the anticipated increase in demand for corticosteroids such as prednisone and prednisolone, as orally taken tablets, is likely to provide impetus to the segment.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Analysis by Region

The segmentation based on the region includes the United States, EU-4 (Germany, France, Italy, Spain), and the United Kingdom, Japan, and India. The United States holds a substantial market value driven by the presence of technologically advanced healthcare infrastructure and a favourable regulatory environment. A significant portion of the population in the regional market gets affected by chronic inflammatory demyelinating polyneuropathy (CIDP) every year, which directly impacts the market demand. Increased initiatives by the government along with social media campaigns spreading awareness about CIDP are likely to stimulate the market growth in the coming years. Along with United States, EU-4 and the United Kingdom is also expected a notable market share in the forecast period.

Leading Players in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market

The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

CSL Behring

Global biotechnology company CSL Behring is a leading manufacturer of plasma-derived and recombination therapeutics. The company's Hizentra®, a 20% liquid IgG  product for subcutaneous administration, is indicated as a maintenance therapy for adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

ADMA Biologics, Inc.

This biopharmaceutical company specializes in the development of specialty plasma-derived biologics that can help treat immune deficiencies and infectious diseases. The company intends to improve the efficacy and safety of its existing therapies through rigorous research activities and clinical trials.

Pfizer Inc.

Pfizer Inc. invests heavily in the clinical development of various drugs aimed to treat neurological and autoimmune conditions and thus significantly contributes to the chronic inflammatory demyelinating polyneuropathy therapeutics market growth. In February 2021 , the United States Food and Drug Administration (FDA) approved Pfizer's Panzyga® (Immune Globulin Intravenous [Human] – ifas 10 percent Liquid Preparation) indicated to treat chronic inflammatory demyelinating polyneuropathy.

UCB S.A.

Headquartered in Belgium, this multinational biopharmaceutical company has a robust presence in the market. It is involved in the clinical development of CIDP therapeutics.

Other key players in the market include Bio Products Laboratory Ltd., Grifols, Teva Pharmaceutical Industries Ltd., and Sun Pharmaceutical Industries Ltd.

Key Highlights of the Report

Key Questions Answered in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market Report

• What was the chronic inflammatory demyelinating polyneuropathy therapeutics market value in 2023?
• What is the chronic inflammatory demyelinating polyneuropathy therapeutics market forecast outlook for 2024-2032?
• What are the regional markets covered in the EMR report?
• What is market segmentation based on drug type?
• What is market segmentation based on the route of administration?
• What is the market breakup by gender?
• Who are the major end users in the market?
• What are the major distribution channels in the market?
• What are the major factors aiding the chronic inflammatory demyelinating polyneuropathy therapeutics market demand? 
• How has the market performed so far and how is it anticipated to perform in the coming years?
• What are the market's major drivers, opportunities, and restraints? 
• Which regional market is expected to lead the market share in the forecast period? 
• Which country is likely to experience rapid growth during the forecast period? 
• What are the major chronic inflammatory demyelinating polyneuropathy therapeutics market trends?
• How does the rise in the geriatric population impact the market size?
• What drug type will dominate the market share? 
• Which route of administration will experience the highest demand in the market segment?
• Which gender is poised to considerably impact the market demand? 
• Which end user is projected to contribute to the highest market growth?
• Which distribution channel is anticipated to boost the market share?
• Who are the key players involved in the chronic inflammatory demyelinating polyneuropathy therapeutics market?
• What is the patent landscape of the market?
• What are the current unmet needs and challenges in the market?
• How are partnerships, collaborations, mergers and acquisitions among the key market players shaping the market dynamics?